Multiple functions of p27(Kip1) and its alterations in tumor cells: A review

Journal of Cellular Physiology

Volumn 183, Issue 1, 2000, Pages 18-27

  Sgambato, Alessandro ^a   Cittadini, Achille ^a   Faraglia, Beatrice ^a   Weinstein, I Bernard ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RESEARCH; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COLON CANCER; ENZYME REGULATION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ANIMALS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; GENES, TUMOR SUPPRESSOR; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EUKARYOTA;

EID: 0034011051     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S     Document Type: Article

References (132)

1. Kip1 Mol Cell Biol 17:3850-3857.
2. Arber N, Doki Y, Han EK-H, Sgambato A, Zhou P, et al. 1997. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57:1569-1574.
3. Baldassarre G, Belletti B, Bruni P, Boccia A, Trapasso F, et al. 1999. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Invest 104:865-874.
4. Barboule N, Baldin V, Jozan S, Vidal S, Valette A. 1998. Increased level of p21 in human ovarian tumors is associated with increased expression of CDK2, cyclin A and PCNA. Int J Cancer 76:891-896.
5. Kip1, to regions involved in human cancer. Cancer Res 55:1199-1205.
6. Kip1 in sarcoma. Proc Am Assoc Cancer Res 40:687.
7. Kip1. Genes Dev 11:2335-2346.
8. Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227-230.
9. Kip1. J Clin Invest 97:1983-1988.
10. Chen PL, Scully P, Shew JY. 1989. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58:1193-1198.
11. Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA 95:1091-1096.
12. Kip1 in multistage colorectal carcinogenesis. Cancer Res 58:114-122.
13. Kip1 for restriction point control of fibroblasts' cell cycle. Science 272:877-880.
14. Kip1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90:000-000.
15. Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 14:2283-2289.
16. Kip1 on resistance of tumor cells to anticancer agents. Nat Med 2:1204-1210.
17. Kip1 protein in human esophageal cancer cell lines that overexpresses cyclin D1. Carcinogenesis 18:1139-1148.
18. Draetta GF. 1994. Mammalian G1 cyclins. Curr Opin Cell Biol 6:842-846.
19. Kip1 contributes to growth and differentiation of osteoblasts. Cancer Res 59:3705-3711.
20. Durand B, Gao FB, Raff M. 1997. Accumulation of the p27/Kip1 cyclin-dependent kinase inhibitor and the timing of oligodendrocyte differentiation. EMBO J 16:306-317.
21. Elledge SJ, Harper JW. 1994. Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 6:847-852.
22. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, et al. 1997. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57:3381-3385.
23. Kip1 induces drug resistance by preventing apotosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene 18:1411-1418.
24. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E. 1996. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 271:499-502.
25. Kip1-deficient mice Cell 85:733-744.
26. Kip1 is haplo-insufficient for tumour suppression. Nature 396:177-180.
27. Kip1 in primary breast carcinomas. Hum Genet 97-91-94.
28. Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12:2899-2911.
29. Kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94:6380-6385.
30. INK4/MST2-related CDK6 inhibitor, correlates with wild-type Rb function. Genes Dev 8-2939-2952.
31. Kip1 protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 3-2269-2274.
32. Kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ 7:699-710.
33. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261.
34. Harper JW, Adami G, Wei N, Keyomarsi K, Elledge SJ 1993. The p21kd Cdk interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
35. Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. Oncogene 14-2111-2122.
36. Ink4a is associated with, but not sufficient for, induction of squamous differentiation. J Cell Sci 1111:1185-1196.
37. Kip1 in the in vitro differentiation of murine keratinocytes. Cell Growth Differ 8:203-211.
38. Kip1 accumulation during the cell cycle. Science 271:1861-1864.
39. 15INK4B1. Cancer Res 56:722-727.
40. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. 1992. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006.
41. Hirai H, Roussel MF, Kato J, Ashmun RA, Sherr CJ. 1995. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15:2672-2681.
42. Kip1. J Clin Invest 103:597-604.
43. Kip1 degradation through its regulation of cyclin E/CDK2 activity. J Biol Chem 274:3396-3401.
44. Hunter T, Pines J. 1994. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573-582.
45. Ikeda H, Yoshimoto T, Shida N. 1997. Molecular analysis of p21 and p27 genes in human pituitary adenomas. Br J Cancer 76:1119-1123.
46. Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 151:509-519.
47. Johnson D, Frame MC, Wyke JA. 1998. Expression of the v-Src oncoprotein in fibroblasts disrupts normal regulation of the CDK inhibitor p27 and inhibits quiescence. Oncogene 16:2017-2028.
48. Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol 152:585-590.
49. WAF1/Cip1 in human brain tumors.
50. Katayose Y, Kim M, Rakkar ANS, Li Z, Cowan KH, Seth P. 1997. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 57:5441-5445.
51. KIP1) of cyclin-dependent kinase 4 activation. Cell 79:487-496.
52. Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15:629-637.
53. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, et al. 1995. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55:2266-2269.
54. Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol 153:505-513.
55. Kip1. Cell 85:721-732.
56. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, et al. 1999. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene 18:3742-3753.
57. Kranenburg O, Scharnhorst V, van der Eb AJ, Zantema A. 1995. Inhibition of cyclin-dependent kinase triggers neuronal differentiation of mouse neuroblastoma cells. J Cell Biol 131:227-234.
58. Kip1 in a human gastric carcinoma cell line. Cell Growth Differ 8:47-52.
59. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639-649.
60. Levenberg S, Yarden A, Kam Z, Geiger B. 1999. p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry. Oncogene 18:869-876.
61. Li D-M, Sun H. 1998. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 95:15406-15411.
62. Liu M, Lee M, Cohen M, Bommakanti M, Freedman LP. 1996. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153.
63. Kip1 expression in endocrine and other tumors. Am J Pathol 150:401-407.
64. Kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313-323.
65. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, et al. 1997. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231-233.
66. Lod́en M, Nielsen NH, Roos G, Emdin SO, Landberg G. 1999. Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene 18:2557-2566.
67. MacLachlan TK, Sang N, Giordano A. 1995. Cyclins, cyclin-dependent kinases and Cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 5:127-156.
68. Kip1 by the viral E1A oncoprotein in TGFβ-treated cells. Nature 380:262-265.
69. Mang QM, Jones JB, Studzinski GP. 1996. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-Dihydroxyvitamin D3 in HL60 cells. Cancer Res 56:264-267.
70. Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, et al. 1999. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 59:3790-3794.
71. Kip1 in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3). Oncogene 17:2619-2627.
72. Morgan DO. 1995. Principles of CDK regulation. Nature 374:131-134.
73. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, et al. 1997. p27 expression and gastric carcinoma. Nat Med 3:593.
74. Kip1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 86:1924-1930.
75. Sdi1/CIP1/WAF1 EMBO J 14:555-563.
76. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720.
77. Kip1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol 154:119-125.
78. Kip1, a G1-cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. Mol Cell Biol 19:1190-1201.
79. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372:570-573.
80. Kip1 safeguards against inflammatory injury. Nat Med 4:575-580.
81. Kip1 in anchorage-independent cells. Oncogene 16:2575-2583.
82. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, et al. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685.
83. Kip1 binding to newly formed complexes. Oncogene 14:2373-2381.
84. Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, et al. 1995. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 55:1206-1210.
85. Piva R, Cancelli I, Cavalla P, Bortolotto S, Dominguez J, et al. 1999. Proteasome-dependent degradation of p27/Kip1 in gliomas. J Neuropathol Exp Neurol 58:691-696.
86. KIP1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8:9-22.
87. KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
88. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 55:1211-1214.
89. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, et al. 1997. Expression of cell-cycle regulators p27 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3:222-225.
90. Kip1 expression in rodent pituitary cell lines. Am J Pathol
91. Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, et al. 1998. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 101:153-159.
92. Reynisdottir I, Polyak K, Iavarone A, Massague J. 1995. Kip/Cip and INK4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 9:1831-1845.
93. Kip1 by cDNA antisense suppresses quiescence (GO state) in fibroblasts. J Biol Chem 271:18337-18341.
94. Kip1 cyclin-dependent kinase inhibitor bound to the cyclin A-cdk2 complex. Nature 382:325-331.
95. Kip1 expression is inversely proportional to the proliferative index. Am J Pathol 151:151-160.
96. KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene 18:1663-1676.
97. Serrano M, Hannon GJ, Beach D. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707.
98. Kip1. Cancer Res 56:1389-1399.
99. Kip1 expression. Cell Growth Differ 8:393-405.
100. Kip1 in human breast cancers. Clin Cancer Res 3:1879-1887.
101. Kip1 inhibits the growth of both normal and transformed human mammary epithelial cells. Cancer Res 58:3448-3454.
102. Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 59:3245-3250.
103. Kip1 in human colon cancer. Mol Carcinog (in press).
104. Kip1. Genes Dev 11:1464-1478.
105. Sherr CJ. 1994. G1 phase progression: cycling on cue. Cell 79:551-555.
106. Sherr CJ. 1995. D-type cyclins. Trends Biochem Sci 20:187-190.
107. Sherr CJ, Roberts JM. 1995. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163.
108. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, et al. 1994. Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781-3784.
109. Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, et al. 1998. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinomas. Cancer Res 58:1730-1735.
110. Soucek T, Yeung RS, Hengstschlager M. 1998. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci USA 95:15653-15658.
111. Steiner P, Philipp A, Lukas J, Godden-Kent D, Pagano M, et al. 1995. Identification of a myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J 14:4814-4826.
112. Kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 17:5348-5358.
113. Tan P, Cady B, Wanner M, Worland P, Cukor B, et al. 1997. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res 57:1259-1263.
114. Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M. 1998. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 153:681-687.
115. Kip1 accompany glial cell differentiation of central glia-4 cells. J Biol Chem 272:442-447.
116. Kip1 is instigated by Jab1. Nature 398-160-165.
117. Kip1, an inhibitor of G1 cyclin-dependent kinases, uncouple differentiation and growth arrest during the granulosa → luteal transition. Cell Growth Differ 9:787-794.
118. Toyoshima H, Hunter T. 1994. P27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67-74.
119. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58:542-548.
120. Skp2 complex through phosphorylated Thr187 in p27. Curr Biol 9:661-664.
121. Kip1 is abrogated by c-Myc. EMBO J 15:6595-6604.
122. Vlach J, Hennecke S, Amati B. 1997. Phosphorylation-dependent degradation of the cyclin-dependent inhibitor p27. EMBO J 16:5334-5344.
123. Kip1 is localized to the cytosol in Swiss/3T3 cells. Oncogene 18:5204-5210.
124. Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 15:2991-2997.
125. Kip1. J Biol Chem 272:32966-32971.
126. Weinberg RA. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330.
127. Weinstein IB, Zhou P. 1997. Cell cycle control gene defects and human cancers. In: Bertino JR, editor. Encyclopedia of cancer, Vol. 1. New York: Academic. p 256-267.
128. Cip/Waf1 on growth and differentiation in human colon carcinoma cells. Oncogene 18:103-115.
129. Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 88:625-629.
130. Kip1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res 58:1042-1047.
131. Kip1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13:2323-2330.
132. Kip1 in the promyelocytic leukemia cell line HL60 accelerates its lineage-specific differentiation. Anticancer Res (in press).